Chemotherapy Dosing and Ovarian Cancer Survival

What role does BMI play?

Body size should not be a major factor influencing dose reduction decisions in women with ovarian cancer, although women who were obese at diagnosis appeared to have better survival in a study of 806 patients receiving adjuvant first-line therapy of carboplatin and paclitaxel with curative intent. Obese Class-III women received 38% and 45% lower doses in milligrams per kilogram of body weight of paclitaxel and carboplatin, respectively. Researchers found:

• Lower average RDI (ARDI) (<70%) was associated with worse overall (HR=1.62) and ovarian cancer-specific survival (HR=1.69).

• Normal-weight women with dose reduction (ARDI<85%) experienced worse survival (HR=1.50).

• For each BMI category, those with ARDI <85% had worse survival than those without dose reduction.

Citation: Bandera EV, Lee VS, Rodriguez L, Powell CB, Kushi LH. Impact of chemotherapy dosing on ovarian cancer survival according to body mass index. JAMA Oncol. 2015;1(6):737-745. doi: 10.1001/jamaoncol.2015.1796.

Read more on OB. Gyn. News here.

Advertisements

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s